Adult embryonal rhabdomyosarcomas have a poor prognosis, with a 21% five-year survival rate. However, early-stage (Stage II) disease and multimodal treatment including surgery improved outcomes, with recent trends showing fewer recurrences and better survival.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: